Evofem Biosciences, Inc. (EVFM) Fair Value 2026

EVFM · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.2 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (53/100)

Quick Summary — As of 2026-08-27, Evofem Biosciences, Inc. (EVFM) trades at $0.01. QOC: 5.2/10. Value Trap Risk: 53/100 (WARN). 1/13 models active.

Key Facts

Ticker
EVFM
Price
$0.01
Quality Score
5.2/10
Value Trap Risk
53/100
Models Active
1/13
Last Updated
Strength: Regime Cross-Sectional suggests +10.9% upside with 44% confidence
Risk: Value Trap score of 53 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give EVFM?

1 Intrinsic Value Models vs. Current Price ($0.01)

Core Models (Unlocked)
Model Fair Value Upside
Relative · Medium Conviction
 $0.01 +10.9%

All Models Active

All 1 models are displayed above.

What Is Evofem Biosciences, Inc. (EVFM) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Evofem Biosciences, Inc. is potentially undervalued at its current price of $0.01. Based on our 13-model framework, Evofem Biosciences, Inc.'s intrinsic value is estimated at a median fair value of $0.01 — representing +10.9% implied upside — with 1 out of 1 active models confirming this thesis.

What Do the Models Say About EVFM?

1 of 13 models are currently active for EVFM. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does EVFM Rank in Biotechnology?

Among 620 Biotechnology stocks, EVFM ranks #260 by Quality of Company score. CirclFi's QOC score of 5.2/10 evaluates 32 fundamental signals. A score of 5.2 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Evofem Biosciences, Inc.'s positioning within the Biotechnology segment means that R&D burn rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including gene therapy and cell therapy innovation — shape both the opportunity set and risk profile.

Is EVFM a Value Trap?

CirclFi's Value Trap algorithm assigns EVFM a score of 53/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Evofem Biosciences, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Evofem Biosciences, Inc. earns a quality score of 5.2/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency. Our Value Trap detector shows moderate caution signals worth monitoring.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every EVFM valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across EVFM's 1 active models, average confidence is 44%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Evofem Biosciences, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

COYACoya Therapeutics, Inc.QOC 5.2VCNXVaccinex, Inc.QOC 5.2TARAProtara Therapeutics, Inc.QOC 5.2AVIRAtea Pharmaceuticals, Inc.QOC 5.2GOSSGossamer Bio, Inc.QOC 5.2CRBUCaribou Biosciences, Inc.QOC 5.2BMEABiomea Fusion, Inc.QOC 4.6PCSAProcessa Pharmaceuticals, Inc.QOC 3.5HRTXHeron Therapeutics, Inc.QOC 6.4EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: COYA · VCNX · TARA · AVIR · GOSS · CRBU · BMEA · PCSA · HRTX · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to EVFM?

6 companies across all industries closest to EVFM’s Quality of Company score of 5.2/10.

DNUTKrispy Kreme, Inc.QOC 5.2HVIIHennessy Capital Investment Corp. VIIQOC 5.2VIPVulcan Infrastructure and Power Inc.QOC 5.2STNEStoneCo Ltd.QOC 5.2CISOCISO Global Inc.QOC 5.2NVDANVIDIA CorporationQOC 10.0

Read investment analysis: DNUT · HVII · VIP · STNE · CISO · NVDA

Where Does EVFM Sit in CirclFi's Biotechnology Rankings?

EVFM is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Evofem Biosciences, Inc.’s Valuation?

What is Evofem Biosciences, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Evofem Biosciences, Inc. (EVFM). The Quality of Company score is 5.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is EVFM overvalued or undervalued right now?

At $0.01, 1 of 1 active models suggest EVFM may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Evofem Biosciences, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.2 mean for EVFM?

Evofem Biosciences, Inc.'s QOC of 5.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on EVFM?

CirclFi analyzes EVFM with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is EVFM a value trap in 2026?

Evofem Biosciences, Inc.'s Value Trap score is 53/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Evofem Biosciences, Inc. (EVFM) a Quality of Company score of 5.2/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/EVFM/ · Methodology
Primary sources for this EVFM valuation
  • Financial statements: Evofem Biosciences, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001618835) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for EVFM as of ; valuations recomputed .